Viking Therapeutics Inc (NASDAQ:VKTX) Expected to Post Earnings of -$0.13 Per Share

Equities research analysts expect Viking Therapeutics Inc (NASDAQ:VKTX) to report ($0.13) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have provided estimates for Viking Therapeutics’ earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.11). Viking Therapeutics reported earnings of ($0.11) per share during the same quarter last year, which would suggest a negative year over year growth rate of 18.2%. The business is expected to report its next earnings results on Wednesday, November 6th.

On average, analysts expect that Viking Therapeutics will report full-year earnings of ($0.46) per share for the current financial year, with EPS estimates ranging from ($0.61) to ($0.40). For the next financial year, analysts forecast that the firm will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.96) to ($0.47). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that cover Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02).

Several equities analysts recently issued reports on VKTX shares. Stifel Nicolaus started coverage on shares of Viking Therapeutics in a research note on Tuesday, June 25th. They issued a “buy” rating and a $14.00 target price for the company. BidaskClub cut shares of Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday. CIBC started coverage on shares of Viking Therapeutics in a research note on Tuesday, July 16th. They issued an “outperform” rating and a $12.00 target price for the company. Citigroup started coverage on shares of Viking Therapeutics in a research note on Monday, July 15th. They issued an “outperform” rating for the company. Finally, ValuEngine upgraded shares of Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $20.53.

Several large investors have recently added to or reduced their stakes in VKTX. BlackRock Inc. grew its position in shares of Viking Therapeutics by 22.4% in the 4th quarter. BlackRock Inc. now owns 4,099,406 shares of the biotechnology company’s stock worth $31,361,000 after buying an additional 749,505 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Viking Therapeutics by 0.4% in the 4th quarter. Bank of New York Mellon Corp now owns 387,039 shares of the biotechnology company’s stock worth $2,960,000 after buying an additional 1,555 shares during the last quarter. Northern Trust Corp grew its position in shares of Viking Therapeutics by 18.5% in the 4th quarter. Northern Trust Corp now owns 728,958 shares of the biotechnology company’s stock worth $5,576,000 after buying an additional 113,995 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Viking Therapeutics in the 4th quarter worth approximately $1,478,000. Finally, Stifel Financial Corp grew its position in shares of Viking Therapeutics by 30.7% in the 4th quarter. Stifel Financial Corp now owns 22,314 shares of the biotechnology company’s stock worth $176,000 after buying an additional 5,237 shares during the last quarter. 63.96% of the stock is owned by institutional investors and hedge funds.

Shares of VKTX stock traded down $0.13 during trading hours on Friday, hitting $7.13. The company’s stock had a trading volume of 765,835 shares, compared to its average volume of 2,458,445. The stock has a 50 day simple moving average of $8.00. The stock has a market cap of $520.63 million, a PE ratio of -17.83 and a beta of 2.29. Viking Therapeutics has a 12-month low of $6.68 and a 12-month high of $24.00.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Further Reading: How are institutional investors different from individual investors?

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.